Drug Trial Radar · NCT05573477
Evaluation of Efficacy and Safety of ATB-1011+ATB-1012 Co-administration for Essential Hypertension and Type II Diabetes
Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
255
Actual
Start
Nov 16, 2022
Primary completion
Aug 31, 2025
Study completion Feb 28, 2026
Sponsor
- Lead sponsor
- AutotelicbioIndustry
- Sponsor type
- Industry
- First posted
- Oct 10, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate safety and efficacy of ATB-1011 and ATB-1012 co-administration in patients with essential hypertension and type II diabetes mellitus
Conditions
- Essential Hypertension
- Diabetes Mellitus, Type 2
Interventions
ATB-1011Drug
Oral tablet
ATB-1012Drug
Oral tablet
ATB-1013Drug
Oral tablet
ATB-1011 placeboDrug
Placebo matched to ATB-1011
ATB-1012 placeboDrug
Placebo matched to ATB-1012
ATB-1013 placeboDrug
Placebo matched to ATB-1013
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean sitting systolic blood pressure (MSSBP) (ATB-1011+ATB-1012 vs. ATB-1012)Time frame: baseline to Week 12
- Hemoglobin A1c (HbA1c) (ATB-1011+ATB-1012 vs. ATB-1011)Time frame: baseline to Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.